Encapsulating peritoneal sclerosis: The state of affairs

Nature Reviews Nephrology

Volumn 7, Issue 9, 2011, Pages 528-538

  Korte, Mario R ^a   Sampimon, Denise E ^b   Betjes, Michiel G H ^c   Krediet, Raymond T ^b  

^a ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CHLORHEXIDINE; CORTICOSTEROID; CYTOKINE; GROWTH FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PERITONEAL DIALYSIS FLUID; PRACTOLOL; RAPAMYCIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

COMPUTED TOMOGRAPHY SCANNER; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE MARKER; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC PREDISPOSITION; HUMAN; INTESTINE OBSTRUCTION; KIDNEY TRANSPLANTATION; MORTALITY; PATHOGENESIS; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONITIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT DURATION; ULTRAFILTRATION;

HUMANS; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; RISK FACTORS;

EID: 80052270221     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.93     Document Type: Review

References (165)

1. Kawaguchi, Y., Kawanishi, H., Mujais, S., Topley, N. & Oreopoulos, D. G. Encapsulating peritoneal sclerosis: Definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit. Dial. Int. 20 (Suppl. 4), S43-S55 (2000).
2. Brown, M. C., Simpson, K., Kerssens, J. J. & Mactier, R. A. Encapsulating peritoneal sclerosis in the new millennium: A national cohort study. Clin. J. Am. Soc. Nephrol. 4, 1222-1229 (2009).
3. Kawanishi, H. Encapsulating peritoneal sclerosis in Japan: Prospective multicenter controlled study. Perit. Dial. Int. 21 (Suppl. 3), S67-S71 (2001). (Pubitemid 34406780)
4. Rigby, R. J. & Hawley, C. M. Sclerosing peritonitis: The experience in Australia. Nephrol. Dial. Transplant. 13, 154-159 (1998). (Pubitemid 28033596)
5. Kawanishi, H. et al. Encapsulating peritoneal sclerosis in Japan: A prospective, controlled, multicenter study. Am. J. Kidney Dis. 44, 729-737 (2004). (Pubitemid 39237618)
6. Nomoto, Y. et al. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: A report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am. J. Kidney Dis. 28, 420-427 (1996). (Pubitemid 26304423)
7. Summers, A. M. et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int. 68, 2381-2388 (2005). (Pubitemid 43117819)
8. Balasubramaniam, G. et al. The Pan-Thames EPS study: Treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol. Dial. Transplant. 24, 3209-3215 (2009).
9. Johnson, D. W. et al. Encapsulating peritoneal sclerosis: Incidence, predictors, and outcomes. Kidney Int. 77, 904-912 (2010).
10. Korte, M. R., Boeschoten, E. W. & Betjes, M. G. The Dutch EPS Registry: Increasing the knowledge of encapsulating peritoneal sclerosis. Neth. J. Med. 67, 359-362 (2009).
11. Summers, A. M. & Brenchley, P. E. An international encapsulating peritoneal sclerosis registry and DNA bank: Why we need one now. Perit. Dial. Int. 26, 559-563 (2006). (Pubitemid 44669430)
12. Afthentopoulos, I. E., Passadakis, P., Oreopoulos, D. G. & Bargman, J. Sclerosing peritonitis in continuous ambulatory peritoneal dialysis patients: One center's experience and review of the literature. Adv. Ren. Replace. Ther. 5, 157-167 (1998). (Pubitemid 28323575)
13. Korte, M. R. et al. Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation. Nephrol. Dial. Transplant. 22, 2412-2414 (2007). (Pubitemid 47244739)
14. Garosi, G. & Oreopoulos, D. G. No need for an "expiry date" in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis. Int. Urol. Nephrol. 41, 903-907 (2009).
15. Flessner, M. F. The transport barrier in intraperitoneal therapy. Am. J. Physiol. Renal Physiol. 288, F433-F442 (2005). (Pubitemid 40279447)
16. Williams, J. D., Craig, K. J., Topley, N. & Williams, G. T. Peritoneal dialysis: Changes to the structure of the peritoneal membrane and potential for biocompatible solutions. Kidney Int. Suppl. 84, S158-S161 (2003). (Pubitemid 36513400)
17. Mateijsen, M. A. et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit. Dial. Int. 19, 517-525 (1999). (Pubitemid 30015564)
18. Williams, J. D., Craig, K. J., von Ruhland, C., Topley, N. & Williams, G. T. The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int. Suppl. 88, S43-S49 (2003). (Pubitemid 37452813)
19. Honda, K., Nitta, K., Horita, S., Yumura, W. & Nihei, H. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 72, 171-176 (1996). (Pubitemid 26035372)
20. Plum, J. et al. Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int. Suppl. 78, S42-S47 (2001). (Pubitemid 32144068)
21. Nakayama, M. et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int. 51, 182-186 (1997). (Pubitemid 27064536)
22. Yamada, K. et al. Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure. Clin. Nephrol. 42, 354-361 (1994).
23. Honda, K. et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol. Dial. Transplant. 14, 1541-1549 (1999). (Pubitemid 29241752)
24. Kim, Y. S. et al. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-β. J. Lab. Clin. Med. 138, 59-68 (2001). (Pubitemid 32589202)
25. Schwenger, V. et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J. Am. Soc. Nephrol. 17, 199-207 (2006).
26. De Vriese, A. S., Flyvbjerg, A., Mortier, S., Tilton, R. G. & Lameire, N. H. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J. Am. Soc. Nephrol. 14, 2109-2118 (2003). (Pubitemid 36909919)
27. Twardowski, Z. J. et al. Peritoneal equilibration test. Perit. Dial. Bull. 7, 138-147 (1987). (Pubitemid 18014430)
28. Park, M. S., Lee, H. A., Chu, W. S., Yang, D. H. & Hwang, S. D. Peritoneal accumulation of AGE and peritoneal membrane permeability. Perit. Dial. Int. 20, 452-460 (2000).
29. Smit, W., Parikova, A., Struijk, D. G. & Krediet, R. T. The difference in causes of early and late ultrafiltration failure in peritoneal dialysis. Perit. Dial. Int. 25 (Suppl. 3), S41-S45 (2005). (Pubitemid 40883213)
30. Garosi, G. Different aspects of peritoneal damage: Fibrosis and sclerosis. Contrib. Nephrol. 163, 45-53 (2009).
31. Honda, K. et al. Histologic criteria for diagnosing encapsulating peritoneal sclerosis in continuous ambulatory peritoneal dialysis patients. Adv. Perit. Dial. 19, 169-175 (2003).
32. Garosi, G., Di Paolo, N., Sacchi, G. & Gaggiotti, E. Sclerosing peritonitis: A nosological entity. Perit. Dial. Int. 25 (Suppl. 3), S110-S112 (2005). (Pubitemid 40883231)
33. Sherif, A. M. et al. Comparison between the pathology of encapsulating sclerosis and simple sclerosis of the peritoneal membrane in chronic peritoneal dialysis. Ther. Apher. Dial. 12, 33-41 (2008). (Pubitemid 351197450)
34. Verger, C. & Celicout, B. Peritoneal permeability and encapsulating peritonitis. Lancet 1, 986-987 (1985). (Pubitemid 15123994)
35. Krediet, R. T. et al. The time course of peritoneal transport kinetics in continuous ambulatory peritoneal dialysis patients who develop sclerosing peritonitis. Am. J. Kidney Dis. 13, 299-307 (1989). (Pubitemid 19109081)
36. Mactier, R. A. The spectrum of peritoneal fibrosing syndromes in peritoneal dialysis. Adv. Perit. Dial. 16, 223-228 (2000).
37. Paniagua, R. et al. Correlation between peritoneal equilibration test and dialysis adequacy and transport test, for peritoneal transport type characterization. Perit. Dial. Int. 20, 53-59 (2000). (Pubitemid 30184771)
38. Lambie, M. L., John, B., Mushahar, L., Huckvale, C. & Davies, S. J. The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made. Kidney Int. 78, 611-618 (2010).
39. Sampimon, D. E., Coester, A. M., Struijk, D. G. & Krediet, R. T. The time course of peritoneal transport parameters in peritoneal dialysis patients who develop encapsulating peritoneal sclerosis. Nephrol. Dial. Transplant. 26, 291-298 (2010).
40. Sampimon, D. E., Coester, A. M., Struijk, D. G. & Krediet, R. T. Time course of peritoneal transport parameters in peritoneal dialysis patients who develop peritoneal sclerosis. Adv. Perit. Dial. 23, 107-111 (2007).
41. Brown, E. A. et al. Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: Position paper for ISPD. Perit. Dial. Int. 29, 595-600 (2009).
42. Connolly, D. T. et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 84, 1470-1478 (1989). (Pubitemid 19272234)
43. Ha, H., Cha, M. K., Choi, H. N. & Lee, H. B. Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit. Dial. Int. 22, 171-177 (2002). (Pubitemid 34546327)
44. Mandl-Weber, S., Cohen, C. D., Haslinger, B., Kretzler, M. & Sitter, T. Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int. 61, 570-578 (2002). (Pubitemid 34102598)
45. Io, H. et al. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int. 65, 1927-1936 (2004). (Pubitemid 38591045)
46. Yoshio, Y. et al. TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int. 66, 1677-1685 (2004). (Pubitemid 39298405)
47. Tanabe, K. et al. Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model. Kidney Int. 71, 227-238 (2007). (Pubitemid 46160923)
48. Zweers, M. M., de Waart, D. R., Smit, W., Struijk, D. G. & Krediet, R. T. Growth factors VEGF and TGF-β1 in peritoneal dialysis. J. Lab. Clin. Med. 134, 124-132 (1999). (Pubitemid 29375441)
49. Zweers, M. M., Struijk, D. G., Smit, W. & Krediet, R. T. Vascular endothelial growth factor in peritoneal dialysis: A longitudinal follow-up. J. Lab. Clin. Med. 137, 125-132 (2001). (Pubitemid 32116955)
50. Patel, P. et al. Smad3-dependent and -independent pathways are involved in peritoneal membrane injury. Kidney Int. 77, 319-328 (2010).
51. Bonniaud, P. et al. Smad3 null mice develop airspace enlargement and are resistant to TGF-β-mediated pulmonary fibrosis. J. Immunol. 173, 2099-2108 (2004). (Pubitemid 38971648)
52. Sato, M., Muragaki, Y., Saika, S., Roberts, A. B. & Ooshima, A. Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J. Clin. Invest. 112, 1486-1494 (2003). (Pubitemid 38056275)
53. Border, W. A. & Noble, N. A. Transforming growth factor β in tissue fibrosis. N. Engl. J. Med. 331, 1286-1292 (1994). (Pubitemid 24333194)
54. Rougier, J. P., Guia, S., Hagege, J., Nguyen, G. & Ronco, P. M. PAI-1 secretion and matrix deposition in human peritoneal mesothelial cell cultures: Transcriptional regulation by TGF-β1. Kidney Int. 54, 87-98 (1998). (Pubitemid 28288023)
55. Martin, J., Yung, S., Robson, R. L., Steadman, R. & Davies, M. Production and regulation of matrix metalloproteinases and their inhibitors by human peritoneal mesothelial cells. Perit. Dial. Int. 20, 524-533 (2000).
56. Hung., K. Y., Huang, J. W., Chen, C. T., Lee, P. H. & Tsai, T. J. Pentoxifylline modulates intracellular signalling of TGF-β in cultured human peritoneal mesothelial cells: Implications for prevention of encapsulating peritoneal sclerosis. Nephrol. Dial. Transplant. 18, 670-676 (2003).
57. Hung, K. Y. et al. Dipyridamole inhibits TGF-β-induced collagen gene expression in human peritoneal mesothelial cells. Kidney Int. 60, 1249-1257 (2001).
58. Liu, L. et al. Prolonged peritoneal gene expression using a helper-dependent adenovirus. Perit. Dial. Int. 29, 508-516 (2009).
59. Margetts, P. J. et al. Transient overexpression of TGF-β1 induces epithelial mesenchymal transition in the rodent peritoneum. J. Am. Soc. Nephrol. 16, 425-436 (2005). (Pubitemid 41725138)
60. Margetts, P. J. et al. Gene transfer of transforming growth factor-β1 to the rat peritoneum: Effects on membrane function. J. Am. Soc. Nephrol. 12, 2029-2039 (2001). (Pubitemid 32880339)
61. Liu, Y. Epithelial to mesenchymal transition in renal fibrogenesis: Pathologic significance, molecular mechanism, and therapeutic intervention. J. Am. Soc. Nephrol. 15, 1-12 (2004). (Pubitemid 38020692)
62. Jimenez-Heffernan, J. A. et al. Immunohistochemical characterization of fibroblast subpopulations in normal peritoneal tissue and in peritoneal dialysis-induced fibrosis. Virchows Arch. 444, 247-256 (2004). (Pubitemid 38446437)
63. Yanez-Mo, M. et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N. Engl. J. Med. 348, 403-413 (2003). (Pubitemid 36159357)
64. Yang, A. H., Chen, J. Y. & Lin, J. K. Myofibroblastic conversion of mesothelial cells. Kidney Int. 63, 1530-1539 (2003). (Pubitemid 36350019)
65. Selgas, R. et al. Epithelial-to-mesenchymal transition of the mesothelial cell-its role in the response of the peritoneum to dialysis. Nephrol. Dial. Transplant. 21 (Suppl. 2), ii2-ii7 (2006). (Pubitemid 44018935)
66. Shirai, K. et al. A new model of anterior subcapsular cataract: Involvement of TGFβ/Smad signaling. Mol. Vis. 12, 681-691 (2006). (Pubitemid 43905816)
67. Banh, A. et al. Lens-specific expression of TGF-β induces anterior subcapsular cataract formation in the absence of Smad3. Invest. Ophthalmol. Vis. Sci. 47, 3450-3460 (2006). (Pubitemid 351639710)
68. Aroeira, L. S. et al. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: Role of vascular endothelial growth factor. Am. J. Kidney Dis. 46, 938-948 (2005). (Pubitemid 41505470)
69. Hirahara, I. et al. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis-a multicentre study in Japan. Nephrol. Dial. Transplant. 22, 560-567 (2007). (Pubitemid 46189902)
70. De Vriese, A. S., Tilton, R. G., Mortier, S. & Lameire, N. H. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol. Dial. Transplant. 21, 2549-2555 (2006). (Pubitemid 44644530)
71. Cano, A. et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2, 76-83 (2000).
72. Del Peso, G. et al. Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport. Kidney Int. Suppl. 108, S26-S33 (2008). (Pubitemid 351466514)
73. Kawanishi, H., Watanabe, H., Moriishi, M. & Tsuchiya, S. Successful surgical management of encapsulating peritoneal sclerosis. Perit. Dial. Int. 25 (Suppl. 4), S39-S47 (2005). (Pubitemid 41600358)
74. Honda, K. & Oda, H. Pathology of encapsulating peritoneal sclerosis. Perit. Dial. Int. 25 (Suppl. 4), S19-S29 (2005). (Pubitemid 41600356)
75. Augustine, T., Brown, P. W., Davies, S. D., Summers, A. M. & Wilkie, M. E. Encapsulating peritoneal sclerosis: Clinical significance and implications. Nephron Clin. Pract. 111, c149-c154 (2009).
76. Summers, A. M., Hoff, C. M. & Topley, N. How can genetic advances impact on experimental models of encapsulating peritoneal sclerosis? Perit. Dial. Int. 28 (Suppl. 5), S16-S20 (2008).
77. Watson, C. J., Webb, N. J., Bottomley, M. J. & Brenchley, P. E. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: Correlation with variation in VEGF protein production. Cytokine 12, 1232-1235 (2000). (Pubitemid 30611801)
78. Sampimon, D. E., Vlijm, A., Phoa, S. S., Krediet, R. T. & Struijk, D. G. Encapsulating peritoneal sclerosis in a peritoneal dialysis patient using biocompatible fluids only: Is Alport syndrome a risk factor? Perit. Dial. Int. 30, 240-242 (2010).
79. Williams, J. D. et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J. Am. Soc. Nephrol. 13, 470-479 (2002). (Pubitemid 34106290)
80. Korte, M. R. et al. Risk factors associated with encapsulating peritoneal sclerosis in Dutch EPS study. Perit. Dial. Int. 31, 269-278 (2011).
81. Habib, A. M., Preston, E. & Davenport, A. Risk factors for developing encapsulating peritoneal sclerosis in the icodextrin era of peritoneal dialysis prescription. Nephrol. Dial. Transplant. 25, 1633-1638 (2010).
82. Nakayama, M. et al. Risk factors and preventive measures for encapsulating peritoneal sclerosis-Jikei experience. Adv. Perit. Dial. 18, 144-148 (2002).
83. Moriishi, M. et al. Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis. Adv. Perit. Dial. 18, 149-153 (2002).
84. Yamamoto, T., Nagasue, K., Okuno, S. & Yamakawa, T. The role of peritoneal lavage and the prognostic significance of mesothelial cell area in preventing encapsulating peritoneal sclerosis. Perit. Dial. Int. 30, 343-352 (2010).
85. Linden, T., Forsback, G., Deppisch, R., Henle, T. & Wieslander, A. 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis. Perit. Dial. Int. 18, 290-293 (1998). (Pubitemid 28365121)
86. Hendriks, P. M. et al. Peritoneal sclerosis in chronic peritoneal dialysis patients: Analysis of clinical presentation, risk factors, and peritoneal transport kinetics. Perit. Dial. Int. 17, 136-143 (1997). (Pubitemid 27474769)
87. Boulanger, E. Peritoneal and systemic inflammation: The benefits of using biocompatible peritoneal dialysis fluids. Perit. Dial. Int. 28, 28-31 (2008). (Pubitemid 351566122)
88. Hekking, L. H. et al. Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate- buffered solution. J. Am. Soc. Nephrol. 12, 2775-2786 (2001). (Pubitemid 33115426)
89. Rippe, B. et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int. 59, 348-357 (2001). (Pubitemid 32055244)
90. Williams, J. D. et al. The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int. 66, 408-418 (2004). (Pubitemid 38870119)
91. Dombros, N. et al. European best practice guidelines for peritoneal dialysis. 5 Peritoneal dialysis solutions. Nephrol. Dial. Transplant. 20 (Suppl. 9), ix16-ix20 (2005).
92. Mistry, C. D., Mallick, N. P. & Gokal, R. Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges. Lancet 2, 178-182 (1987).
93. Goodship, T. H. et al. Short-term studies on the use of amino acids as an osmotic agent in continuous ambulatory peritoneal dialysis. Clin. Sci. (Lond.) 73, 471-478 (1987). (Pubitemid 18019693)
94. Martis, L. et al. Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. Lancet 365, 588-594 (2005). (Pubitemid 40247915)
95. Martikainen, T. A., Teppo, A. M., Gronhagen-Riska, C. & Ekstrand, A. V. Glucose-free dialysis solutions: Inductors of inflammation or preservers of peritoneal membrane? Perit. Dial. Int. 25, 453-460 (2005). (Pubitemid 41448400)
96. Posthuma, N. et al. Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime dwell for two years. Perit. Dial. Int. 20, 174-180 (2000).
97. Moriishi, M. & Kawanishi, H. Fibrin degradation products are a useful marker for the risk of encapsulating peritoneal sclerosis. Adv. Perit. Dial. 24, 56-59 (2008).
98. Moriishi, M., Kawanishi, H. & Tsuchiya, S. Impact on peritoneal membrane of use of icodextrin-based dialysis solution in peritoneal dialysis patients. Adv. Perit. Dial. 22, 24-28 (2006).
99. Parikova, A., Zweers, M. M., Struijk, D. G. & Krediet, R. T. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions. Adv. Perit. Dial. 19, 186-190 (2003).
100. Davies, S. J. et al. Icodextrin improves the fluid status of peritoneal dialysis patients: Results of a double-blind randomized controlled trial. J. Am. Soc. Nephrol. 14, 2338-2344 (2003). (Pubitemid 37052381)
101. Bradley, J. A. et al. Sclerosing obstructive peritonitis after continuous ambulatory peritoneal dialysis. Lancet 2, 113-114 (1983). (Pubitemid 13066597)
102. Yamamoto, R. et al. Risk factors for encapsulating peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment. Clin. Exp. Nephrol. 9, 148-152 (2005). (Pubitemid 40875105)
103. Flanigan, M., Anderson, D. & Freeman, R. M. Peritoneal dialysis complicated by fungal peritonitis and peritoneal fibrosis. Am. J. Med. 76, A113-A125 (1984).
104. Chew, C. G., Clarkson, A. R. & Faull, R. J. Relapsing CAPD peritonitis with rapid peritoneal sclerosis due to Haemophilus influenzae. Nephrol. Dial. Transplant. 12, 821-822 (1997). (Pubitemid 27170450)
105. Kim, B. S. et al. Clinical characteristics of dialysis related sclerosing encapsulating peritonitis: Multi-center experience in Korea. Yonsei Med. J. 46, 104-111 (2005). (Pubitemid 40372879)
106. Fieren, M. W., Betjes, M. G., Korte, M. R. & Boer, W. H. Posttransplant encapsulating peritoneal sclerosis: A worrying new trend? Perit. Dial. Int. 27, 619-624 (2007). (Pubitemid 351843476)
107. Kuriyama, S. & Tomonari, H. Corticosteroid therapy in encapsulating peritoneal sclerosis. Nephrol. Dial. Transplant. 16, 1304-1305 (2001). (Pubitemid 32547401)
108. Maluccio, M. et al. Tacrolimus enhances transforming growth factor-β1 expression and promotes tumor progression. Transplantation 76, 597-602 (2003). (Pubitemid 37013269)
109. Roberts, A. B. et al. Transforming growth factor type β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl Acad. Sci. USA 83, 4167-4171 (1986). (Pubitemid 16057012)
110. van Westrhenen, R. et al. Cyclosporin A induces peritoneal fibrosis and angiogenesis during chronic peritoneal exposure to a glucose-based, lactate-buffered dialysis solution in the rat. Blood Purif. 25, 466-472 (2007). (Pubitemid 351194890)
111. Lin, C. H. et al. Sclerosing encapsulating peritonitis in a liver transplant patient: A case report. World J. Gastroenterol. 11, 5412-5413 (2005).
112. Oules, R., Challah, S. & Brunner, F. P. Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol. Dial. Transplant. 3, 66-69 (1988).
113. Brown, P., Baddeley, H., Read, A. E., Davies, J. D. & McGarry, J. Sclerosing peritonitis, an unusual reaction to a β-adrenergic-blocking drug (practolol). Lancet 2, 1477-1481 (1974).
114. Holland, P. Sclerosing encapsulating peritonitis in chronic ambulatory peritoneal dialysis. Clin. Radiol. 41, 19-23 (1990). (Pubitemid 20029962)
115. Krestin, G. P., Kacl, G., Hoffmann, R., Keusch, G. & Burger, H. R. [The imaging diagnosis of sclerosing peritonitis (SP) following continuous ambulatory peritoneal dialysis (CAPD)]. Rofo 157, 506-511 (1992).
116. Campbell, S. et al. Sclerosing peritonitis: Identification of diagnostic, clinical, and radiological features. Am. J. Kidney Dis. 24, 819-825 (1994). (Pubitemid 24350470)
117. Goodlad, C. et al. Screening for encapsulating peritoneal sclerosis in patients on peritoneal dialysis: Role of CT scanning. Nephrol. Dial. Transplant. 26, 1374-1379 (2010).
118. Stafford-Johnson, D. B., Wilson, T. E., Francis, I. R. & Swartz, R. CT appearance of sclerosing peritonitis in patients on chronic ambulatory peritoneal dialysis. J. Comput. Assist. Tomogr. 22, 295-299 (1998). (Pubitemid 28155207)
119. Vlijm, A. et al. Computed tomographic findings characteristic for encapsulating peritoneal sclerosis: A case-control study. Perit. Dial. Int. 29, 517-522 (2009).
120. Tarzi, R. M. et al. Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis. Clin. J. Am. Soc. Nephrol. 3, 1702-1710 (2008).
121. Lien, Y. C. et al. Clinical images: Encapsulating peritoneal sclerosis. CMAJ 181, 177 (2009).
122. Huser, N. et al. Sclerosing encapsulating peritonitis: MRI diagnosis. Eur. Radiol. 16, 238-239 (2006). (Pubitemid 43103590)
123. Nakamoto, H. Encapsulating peritoneal sclerosis-a clinician's approach to diagnosis and medical treatment. Perit. Dial. Int. 25 (Suppl. 4), S30-S38 (2005). (Pubitemid 41600357)
124. Kawaguchi, Y. et al. Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: Diagnosis, predictive markers, treatment, and preventive measures. Perit. Dial. Int. 25 (Suppl. 4), S83-S95 (2005). (Pubitemid 41600364)
125. Breborowicz, A., Breborowicz, M., Pyda, M., Polubinska, A. & Oreopoulos, D. Limitations of CA125 as an index of peritoneal mesothelial cell mass. Nephron Clin. Pract. 100, c46-c51 (2005). (Pubitemid 40868662)
126. Pannekeet, M. M., Koomen, G. C., Struijk, D. G. & Krediet, R. T. Dialysate CA125 in stable CAPD patients: No relation with transport parameters. Clin. Nephrol. 44, 248-254 (1995).
127. Do, J. Y. et al. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis. Perit. Dial. Int. 28 (Suppl. 3), S101-S106 (2008).
128. Sampimon, D. E. et al. Early diagnostic markers for encapsulating peritoneal sclerosis: A case-control study. Perit. Dial. Int. 30, 163-169 (2010).
129. Vlijm, A., de Waart, D. R., Zweers, M. M. & Krediet, R. T. Effluent hydroxyproline in experimental peritoneal dialysis. Perit. Dial. Int. 27, 210-213 (2007). (Pubitemid 46795879)
130. Cho, J. H. et al. Impact of systemic and local peritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: A 1-year prospective study. Nephrol. Dial. Transplant. 25, 1964-1973 (2010).
131. Szeto, C. C. et al. Dialysate hyaluronan concentration predicts survival but not peritoneal sclerosis in continuous ambulatory peritoneal dialysis. Am. J. Kidney Dis. 36, 609-614 (2000).
132. de Freitas, D. et al. Nutritional management of patients undergoing surgery following diagnosis with encapsulating peritoneal sclerosis. Perit. Dial. Int. 28, 271-276 (2008).
133. Kawanishi, H., Moriishi, M. & Tsuchiya, S. Experience of 100 surgical cases of encapsulating peritoneal sclerosis: Investigation of recurrent cases after surgery. Adv. Perit. Dial. 22, 60-64 (2006).
134. Kawanishi, H., Moriishi, M., Ide, K. & Dohi, K. Recommendation of the surgical option for treatment of encapsulating peritoneal sclerosis. Perit. Dial. Int. 28 (Suppl. 3), S205-S210 (2008).
135. Bhandari, S., Wilkinson, A. & Sellars, L. Sclerosing peritonitis: Value of immunosuppression prior to surgery. Nephrol. Dial. Transplant. 9, 436-437 (1994). (Pubitemid 24136283)
136. Wong, C. F., Beshir, S., Khalil, A., Pai, P. & Ahmad, R. Successful treatment of encapsulating peritoneal sclerosis with azathioprine and prednisolone. Perit. Dial. Int. 25, 285-287 (2005). (Pubitemid 40724209)
137. Rajani, R., Smyth, J., Koffman, C. G., Abbs, I. & Goldsmith, D. J. Differential Effect of sirolimus vs prednisolone in the treatment of sclerosing encapsulating peritonitis. Nephrol. Dial. Transplant. 17, 2278-2280 (2002). (Pubitemid 35446697)
138. Lafrance, J. P. et al. Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy. Am. J. Kidney Dis. 51, e7-e10 (2008).
139. Junor, B. J. & McMillan, M. A. Immunosuppression in sclerosing peritonitis. Adv. Perit. Dial. 9, 187-189 (1993).
140. Fagugli, R. M., Selvi, A., Quintaliani, G., Bianchi, M. & Buoncristiani, U. Immunosuppressive treatment for sclerosing peritonitis. Nephrol. Dial. Transplant. 14, 1343-1345 (1999).
141. van Bommel, E. F., Hendriksz, T. R., Huiskes, A. W. & Zeegers, A. G. Brief communication: Tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann. Intern. Med. 144, 101-106 (2006). (Pubitemid 46768228)
142. Allaria, P. M., Giangrande, A., Gandini, E. & Pisoni, I. B. Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: Tamoxifen as a new therapeutic agent? J. Nephrol. 12, 395-397 (1999). (Pubitemid 30014653)
143. Eltoum, M. A., Wright, S., Atchley, J. & Mason, J. C. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit. Dial. Int. 26, 203-206 (2006). (Pubitemid 44336172)
144. Korte, M. R. et al. Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: Results of the Dutch Multicentre EPS Study. Nephrol. Dial Transplant. 26, 691-697 (2010).
145. Noh, H. et al. Angiotensin II mediates high glucose-induced TGF-β1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit. Dial. Int. 25, 38-47 (2005). (Pubitemid 40378496)
146. Kyuden, Y., Ito, T., Masaki, T., Yorioka, N. & Kohno, N. Tgf-β1 induced by high glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. Perit. Dial. Int. 25, 483-491 (2005). (Pubitemid 41448405)
147. Wolf, G. & Neilson, E. G. Angiotensin II as a renal growth factor. J. Am. Soc. Nephrol. 3, 1531-1540 (1993).
148. Subeq, Y. M. et al. Valsartan decreases TGF-β1 production and protects against chlorhexidine digluconate-induced liver peritoneal fibrosis in rats. Cytokine 53, 223-230 (2011).
149. Bozkurt, D. et al. The effects of renin-angiotensin system inhibition on regression of encapsulating peritoneal sclerosis. Perit. Dial. Int. 28 (Suppl. 5), S38-S42 (2008).
150. Kolesnyk, I. et al. Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients. Perit. Dial. Int. 27, 446-453 (2007). (Pubitemid 47207733)
151. Sampimon, D. E. et al. Use of angiotensin II inhibitors in patients that develop encapsulating peritoneal sclerosis. Perit. Dial. Int. 30, 656-659 (2010).
152. Zemel, D. et al. Appearance of tumor necrosis factor-a and soluble TNF-receptors I and II in peritoneal effluent of CAPD. Kidney Int. 46, 1422-1430 (1994).
153. Patel, P. et al. Platelet derived growth factor B and epithelial mesenchymal transition of peritoneal mesothelial cells. Matrix Biol. 29, 97-106 (2010).
154. Mizutani, M. et al. Connective tissue growth factor (CTGF/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate. Am. J. Physiol. Renal. Physiol. 298, F721-F733 (2010).
155. Ogata, S., Yorioka, N. & Kohno, N. Glucose and prednisolone alter basic fibroblast growth factor expression in peritoneal mesothelial cells and fibroblasts. J. Am. Soc. Nephrol. 12, 2787-2796 (2001). (Pubitemid 33115427)
156. Vargha, R. et al. Ex vivo reversal of in vivo transdifferentiation in mesothelial cells grown from peritoneal dialysate effluents. Nephrol. Dial. Transplant. 21, 2943-2947 (2006). (Pubitemid 44542254)
157. Throckmorton, D. C., Brogden, A. P., Min, B., Rasmussen, H. & Kashgarian, M. PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int. 48, 111-117 (1995).
158. Katsutani, M., Ito, T., Masaki, T., Kohno, N. & Yorioka, N. Glucose-based PD solution, but not icodextrin-based PD solution, induces plasminogen activator inhibitor-1 and tissue-type plasminogen activator in human peritoneal mesothelial cells via ERK1/2. Ther. Apher. Dial. 11, 94-100 (2007). (Pubitemid 46449868)
159. Kurata, K. et al. Tissue-type plasminogen activator deficiency attenuates peritoneal fibrosis in mice. Am. J. Physiol. Renal Physiol. 297, F1510-F1517 (2009).
160. Collier, I. E. et al. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J. Biol. Chem. 263, 6579-6587 (1988).
161. Kim, J. J. et al. High glucose decreases collagenase expression and increases TIMP expression in cultured human peritoneal mesothelial cells. Nephrol. Dial. Transplant. 23, 534-541 (2008).
162. Hirahara, I., Ogawa, Y., Kusano, E. & Asano, Y. Activation of matrix metalloproteinase-2 causes peritoneal injury during peritoneal dialysis in rats. Nephrol. Dial. Transplant. 19, 1732-1741 (2004). (Pubitemid 38961381)
163. Ro, Y. et al. Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol. Dial. Transplant. 22, 2838-2848 (2007). (Pubitemid 350093438)
164. Alscher, D. M., Braun, N., Biegger, D. & Fritz, P. Peritoneal mast cells in peritoneal dialysis patients, particularly in encapsulating peritoneal sclerosis patients. Am. J. Kidney. Dis. 49, 452-461 (2007).
165. Leibovich, S. J. et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-a. Nature 329, 630-632 (1987). (Pubitemid 17140112)